142 related articles for article (PubMed ID: 7796671)
1. The host response to lesions induced by human papillomavirus.
Stanley M; Coleman N; Chambers M
Ciba Found Symp; 1994; 187():21-32; discussion 32-44. PubMed ID: 7796671
[TBL] [Abstract][Full Text] [Related]
2. "Natural" presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness.
Chambers MA; Wei Z; Coleman N; Nash AA; Stanley MA
Eur J Immunol; 1994 Mar; 24(3):738-45. PubMed ID: 8125141
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
4. The role of the immune system in anogenital human papillomavirus.
Frazer IH
Australas J Dermatol; 1998 Nov; 39 Suppl 1():S5-7. PubMed ID: 9842093
[TBL] [Abstract][Full Text] [Related]
5. The immunology of genital human papilloma virus infection.
Stanley M
Eur J Dermatol; 1998; 8(7 Suppl):8-12; discussion 20-2. PubMed ID: 10387957
[TBL] [Abstract][Full Text] [Related]
6. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B- or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein.
Herd K; Fernando GJ; Dunn LA; Frazer IH; Lambert P; Tindle RW
Virology; 1997 Apr; 231(1):155-65. PubMed ID: 9143315
[TBL] [Abstract][Full Text] [Related]
7. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
8. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes.
Facchinetti V; Seresini S; Longhi R; Garavaglia C; Casorati G; Protti MP
Eur J Immunol; 2005 Mar; 35(3):806-15. PubMed ID: 15719368
[TBL] [Abstract][Full Text] [Related]
10. Immunologic responses to human papillomavirus infection.
Gissmann L
Obstet Gynecol Clin North Am; 1996 Sep; 23(3):625-39. PubMed ID: 8869949
[TBL] [Abstract][Full Text] [Related]
11. Immune evasion in human papillomavirus-associated cervical cancer.
Tindle RW
Nat Rev Cancer; 2002 Jan; 2(1):59-65. PubMed ID: 11902586
[TBL] [Abstract][Full Text] [Related]
12. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA.
Clawson GA; Miranda GQ; Sivarajah A; Xin P; Pan W; Thiboutot D; Christensen ND
Gene Ther; 2004 Sep; 11(17):1331-41. PubMed ID: 15229628
[TBL] [Abstract][Full Text] [Related]
14. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
Lee DW; Anderson ME; Wu S; Lee JH
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
[TBL] [Abstract][Full Text] [Related]
15. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
17. HPV modulation of host immune responses.
Feller L; Wood NH; Khammissa RA; Chikte UM; Meyerov R; Lemmer J
SADJ; 2010 Jul; 65(6):266-8. PubMed ID: 20879650
[TBL] [Abstract][Full Text] [Related]
18. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous and mucosal human papillomavirus E4 proteins form intermediate filament-like structures in epithelial cells.
Roberts S; Ashmole I; Johnson GD; Kreider JW; Gallimore PH
Virology; 1993 Nov; 197(1):176-87. PubMed ID: 8212552
[TBL] [Abstract][Full Text] [Related]
20. Detection of capsid antigen of human papillomavirus (HPV) in benign lesions of female genital tract using anti-HPV monoclonal antibody.
Iwasaki T; Sata T; Sugase M; Sato Y; Kurata T; Suzuki K; Ohmoto H; Iwamoto S; Matsukura T
J Pathol; 1992 Nov; 168(3):293-300. PubMed ID: 1335045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
